Project Grant R21AI195409
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Trustees of Columbia University in the City of New York a Project Grant of $3.14 million under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 6, 2026, with completion targeted for January 31, 2030. The research focuses on regulatory T cell (Treg) memory in human tissues, leveraging Columbia's organ donor tissue resource for human immunology to characterize...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Columbia University a $239,135 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate a high-speed magnetics-based method for mapping the mechanical properties of tissues. The award, obligated on August 11, 2025, with a completion date of July 31, 2027, supports the creation of devices, control systems, and protocols that measure tissue...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $246,562 to The Trustees of Columbia University in the City of New York (Health Sciences Division) on May 26, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support basic biomedical research investigating chromatin-associated RNA processing mechanisms in early B-cell development. The research project, which extends through November 30, 2027, focuses...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Columbia University's Health Sciences Division a $515,387 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 11, 2025, with a completion date of July 31, 2030. This research project will investigate the mechanisms underlying how long 3' untranslated regions (3'UTRs) form in neuronal RNA and their role in triggering autoinflammatory disease....
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Trustees of Columbia University in the City of New York a Project Grant of $452,375 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of tissue-resident T cells in osteoarthritis and their contribution to inflammatory arthritis induced by immune checkpoint inhibitors (ICIs). The research addresses a critical clinical challenge in cancer...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Columbia University's Health Sciences Division a Project Grant of $246,750 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period August 1, 2025 through July 31, 2027. This award supports a systematic investigation of T Follicular Helper (TFH) cells and peripheral helper T cells (TPH) across lymphoid and mucosal tissues in human subjects. The research leverages...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Trustees of Columbia University in the City of New York a Project Grant totaling $764,591 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a five-year research project running from August 1, 2025, through July 31, 2030. This research initiative investigates the differential regulation of cell cycle entry and apoptosis in cytolytic lymphocytes, specifically...
- Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant of $761,840 to The Trustees of Columbia University in the City of New York (Health Sciences Division) under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 5, 2025, with a completion date of July 31, 2030. This research project addresses cardiac allograft vasculopathy (CAV), the leading cause of morbidity and mortality following heart transplantation, by...
- Federal Project Grant Award Summary New York University School of Medicine received a $755,801 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded February 3, 2026, with completion targeted for January 31, 2031. The research project investigates the regulatory mechanisms controlling CD4+ and CD8+ T cell function through examination of the CLNS1A protein, a molecule critical to T...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Columbia University $540,818 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 6, 2025, for a five-year project concluding July 31, 2030. This Project Grant supports fundamental research investigating the interdependency of chemical, structural, and physiological heterogeneity in Pseudomonas aeruginosa biofilms. The research addresses critical gaps in...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Trustees of Columbia University in the City of New York $452,375 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct in vivo profiling studies of Chimeric Autoantibody Receptor T Cell (CAART) therapy for muscle-specific tyrosine kinase (MuSK) myasthenia gravis. The award, effective February 6, 2026, through January 31, 2028, supports investigation of immune profiles before and after CAART infusion to identify biomarkers of safety and efficacy and elucidate the cellular mechanisms of MuSK-CAART in human patients. This research represents a precision immunotherapy approach designed to eliminate disease-causing autoimmune B cells while preserving healthy B cell populations, thereby avoiding risks associated with general immune suppression. The funded research builds upon completed clinical trials demonstrating that four of the first six MuSK-CAART-treated patients experienced improvement in clinical disease activity scores associated with CAART expansion and persistence. Columbia's Health Sciences Division will evaluate pathways activated in MuSK-CAART and host immune cells to advance understanding of this novel cellular immunotherapy and inform engineering strategies for next-generation precision autoimmunity treatments. The work contributes to NIAID's mission to support biomedical research and development of therapeutic interventions for infectious, immunologic, and allergic diseases.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $452.4k | 2/6/26 |